A pilot phase 1 trial evaluated neoadjuvant modified FOLFIRINOX combined with nivolumab in pancreatic ductal adenocarcinoma (PDAC) and reported encouraging safety and preliminary activity, according to investigators Wainberg, Link and Premji. The study explored combining a multi-agent chemotherapy backbone with PD‑1 blockade prior to surgery in this historically immunotherapy‑resistant cancer. Early results suggest the combination can be delivered in the perioperative window with manageable toxicity and signals of tumor response that may increase resection rates. Investigators emphasized feasibility data necessary to move into larger neoadjuvant or randomized studies. If validated in expanded cohorts, the regimen could reshape the standard of care for selected resectable or borderline-resectable PDAC patients and inform biomarker-driven patient selection for immune-chemotherapy combinations.